Mineralys Therapeutics, Inc.
MLYSHealthcareNASDAQBiotechnology · Last scanned Jul 18, 2026
Scan Results
Daily timeframeMineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. At a $2.39B market cap, Mineralys Therapeutics, Inc. ranks as a mid-cap company within healthcare. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea.
Market Cap
$2.39B
Beta
0.65
P/E (TTM)
—
P/E (Fwd)
-12.92
EPS (TTM)
$-1.97
EPS (Fwd)
$-2.10
ROE
-31.0%
ROA
-21.3%
Cash
$646.1M
Total Debt
$0
Free CF
-$78.5M
52W Change
90.4%
Annual Financials
Cash vs Debt
Mineralys Therapeutics, Inc. reports $646.1M in cash and $0 in total debt. The company is burning cash, with free cash flow at -$78.5M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -31.0%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
With a beta below 0.7, Mineralys Therapeutics, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Mineralys Therapeutics, Inc. and its sector.